Daily Respiratory Research Analysis
Analyzed 170 papers and selected 3 impactful papers.
Summary
Analyzed 170 papers and selected 3 impactful articles.
Selected Articles
1. Effect of therapeutic interventions combined with lung-protective ventilation on long-term mortality of patients with acute respiratory distress syndrome: a network meta-analysis.
A Bayesian network meta-analysis of 22 RCTs (n=8,653) compared adjuncts to lung-protective ventilation in ARDS and suggests that prone positioning reduces 180-day mortality versus LPV alone. Open-lung strategies showed no benefit, while VV ECMO, neuromuscular blockade, and corticosteroids may reduce mortality with very low certainty; high-frequency oscillatory ventilation may increase mortality.
Impact: This synthesis elevates long-term survival as an outcome and clarifies which adjuncts to LPV likely matter most for ARDS, directly informing bedside practice and guideline updates.
Clinical Implications: Prioritize early prone positioning in moderate-to-severe ARDS to impact long-term survival; avoid routine HFOV; consider VV ECMO, NMBA, and corticosteroids selectively, acknowledging uncertainty and patient selection.
Key Findings
- Across 22 RCTs (8,653 participants), prone positioning reduced 180-day mortality versus LPV alone.
- Open-lung strategy did not reduce 180-day mortality relative to LPV.
- VV ECMO, neuromuscular blockade, and corticosteroids may reduce 180-day mortality but with very low certainty.
- High-frequency oscillatory ventilation may increase 180-day mortality.
- Bayesian survival-curve NMA estimated intervention-specific survival probabilities at 180 days (LPV baseline ≈0.52).
Methodological Strengths
- Pre-registered (PROSPERO) Bayesian network meta-analysis of survival curves across 22 RCTs
- Systematic search of six databases with dual independent screening and PRISMA reporting
Limitations
- Extrapolation to 180-day mortality for 16 trials may introduce model-dependent uncertainty
- Heterogeneity and very low certainty for several adjuncts; inhaled vasodilator trials not included
Future Directions: Prospective trials to confirm long-term benefits of prone positioning, head-to-head comparisons of adjuncts, and patient-level meta-analyses to refine selection criteria.
PURPOSE: Long-term effects of ventilatory strategies/adjunctive therapies received in the intensive care unit on mortality of patients with acute respiratory distress syndrome (ARDS) is uncertain. To explore 180-day mortality in adult patients with ARDS, we conducted a network meta-analysis (NMA) comparing the effects of various prespecified interventions added to lung-protective ventilation (LPV). SOURCE: We systematically searched six databases on 8 November 2024. Two reviewers independently identified eligible randomized clinical trials with published Kaplan-Meier curves, exploring prespecified interventions combined with LPV and LPV alone. Data were synthesized with NMA of survival curves using Bayesian random effects fractional polynomial models. PRINCIPAL FINDINGS: Twenty-two trials with 8,653 participants assessed six different interventions added to LPV (open lung strategy, neuromuscular blockade [NMBA], corticosteroids, high-frequency oscillatory ventilation [HFOV], prone positioning, and venovenous extracorporeal membrane oxygenation [VV ECMO]), compared with LPV alone. We did not include inhaled pulmonary vasodilator trials. The primary NMA computed survival probability of each intervention on the basis of survival probability of LPV alone at 180 days (0.52; 95% credible interval, 0.49 to 0.55). Compared with LPV alone, 1) the evidence suggests prone positioning results in a reduction in 180-day mortality; 2) an open lung strategy does not reduce 180-day mortality; 3) VV ECMO, NMBA, and corticosteroids may reduce 180-day mortality (very uncertain); and 4) HFOV may increase 180-day mortality (very uncertain). We extrapolated reported mortalities to 180-day mortality in 16 trials, where there might be discrepancy between raw and extrapolated numbers in event rate. CONCLUSIONS: Prone positioning may improve long-term mortality in patients with ARDS. STUDY REGISTRATION: PROSPERO ( CRD42019131849 ); first submitted 26 April 2019. UNLABELLED: RéSUMé: OBJECTIF: Les effets à long terme des stratégies ventilatoires et des traitements d’appoint administrés aux soins intensifs sur la mortalité chez les personnes atteintes de syndrome de détresse respiratoire aiguë (SDRA) demeurent incertains. Afin d’examiner la mortalité à 180 jours chez les adultes ayant un SDRA, nous avons réalisé une méta-analyse en réseau (MAR) comparant l’effet de diverses interventions prédéfinies ajoutées à la ventilation protectrice des poumons (VPP). SOURCES: Nous avons réalisé une recherche systématique dans six bases de données le 8 novembre 2024. Deux personnes ont indépendamment révisé et identifié les études cliniques randomisées admissibles comportant des courbes de Kaplan–Meier publiées et évaluant des interventions prédéfinies combinées à la VPP ou la VPP seule. Les données ont été synthétisées au moyen d’une MAR de courbes de survie reposant sur des modèles bayésiens à effets aléatoires utilisant des polynômes fractionnaires. CONSTATATIONS PRINCIPALES: Vingt-deux études totalisant 8653 participantes et participants ont évalué six interventions ajoutées à la VPP (stratégie à poumon ouvert, blocage neuromusculaire [BNM], corticostéroïdes, ventilation par oscillation à haute fréquence [VOHF], décubitus ventral et oxygénation extracorporelle veino-veineuse [ECMO-VV]) comparativement à la VPP seule. Nous n’avons pas inclus d’études portant sur les vasodilatateurs pulmonaires inhalés. L’analyse principale a estimé la probabilité de survie associée à chaque intervention à partir de la probabilité de survie à 180 jours sous VPP seule (0,52; intervalle de crédibilité à 95 %, 0,49 à 0,55). Comparativement à la VPP seule : 1) les données suggèrent que le décubitus ventral réduit la mortalité à 180 jours; 2) la stratégie à poumon ouvert ne réduit pas la mortalité à 180 jours; 3) l’ECMO-VV, le BNM et les corticostéroïdes pourraient réduire la mortalité à 180 jours (certitude très faible); et 4) la VOHF pourrait augmenter la mortalité à 180 jours (certitude très faible). Nous avons extrapolé les mortalités rapportées à 180 jours de 16 études, ce qui peut entraîner des écarts entre les données brutes et les données extrapolées sur les taux d’événements. CONCLUSION: Le décubitus ventral pourrait améliorer la mortalité à long terme chez les personnes atteintes d’un SDRA. ENREGISTREMENT DE L’éTUDE: PROSPERO ( CRD42019131849 ); première soumission le 26 avril 2019.
2. Hydrogen-Deuterium Exchange Mass Spectrometry Reveals an Antibody-Induced Allosteric Pathway Driving SARS-CoV-2 Spike Trimer Disassembly.
Integrative pulsed HDX-MS, BLI, and nsEM reveal that class V antibody R1-32 engages a semicryptic epitope to trigger an allosteric cascade across a conserved ‘tripartite interface’, propagating via residues 962–977 to drive time-dependent spike trimer disassembly. Eight fully conserved hotspot residues were identified, defining a structure–dynamics roadmap for broad-spectrum antibody design.
Impact: This work uncovers a conserved, targetable allosteric hub in spike and experimentally links antibody binding to trimer disassembly, offering a mechanistic blueprint to outpace variant escape.
Clinical Implications: Antibody and vaccine designs can prioritize conserved, conformation-sensitive epitopes around the tripartite interface to promote destabilization/disassembly, potentially yielding broader neutralization across variants.
Key Findings
- R1-32 (class V) binds a semicryptic epitope and uniquely drives long-range allosteric destabilization across the conserved ‘tripartite interface’.
- Allosteric perturbation propagates via residues 962–977 to the trimer interface, causing time-dependent S-trimer disassembly; nsEM corroborates disassembly.
- ACE2 and class I antibody B38 protect RBD epitopes and induce fusion-priming transitions without trimer disassembly.
- Eight fully conserved residues within the tripartite interface were identified as allosteric hotspots for broad-spectrum antibody targeting.
- Pulsed HDX-MS resolves antibody-mediated dynamic regulation, establishing a structure–dynamics framework for rational antibody design.
Methodological Strengths
- Multi-modal biophysical integration (pulsed HDX-MS, BLI, nsEM) to map structure–dynamics mechanisms
- Comparison of distinct antibody classes and ACE2 on engineered S constructs (S-6P and S-R)
Limitations
- Preclinical, in vitro characterization without in vivo validation of disassembly-driven protection
- Use of engineered spike constructs may not capture all variant-specific conformational landscapes
Future Directions: Engineer and test antibodies targeting the identified hotspots across variants in vivo; quantify disassembly–neutralization relationships and synergy with receptor-blocking antibodies.
The rapid evolution of SARS-CoV-2 necessitates a deeper understanding of antibody neutralization mechanisms to guide the development of broad-spectrum therapies. Here, we integrate pulsed hydrogen-deuterium exchange mass spectrometry (HDX-MS), biolayer interferometry (BLI), and negative-stain electron microscopy (nsEM) to dissect the dynamic regulation of two engineered spike (S) protein constructs, the prefusion-stabilized S-6P and the wild-type-like S-R, by two antibody classes: the noncompetitive RBD class V antibody R1-32 and the competitive class I antibody B38. Our results show that both spike's native receptor, human angiotensin-converting enzyme 2 (ACE2), and B38 primarily protect epitopes within the receptor-binding domain (RBD), inducing a similar level of fusion-priming structural transitions without causing trimer disassembly. In contrast, R1-32 binds to a semicryptic epitope and uniquely triggers long-range allosteric destabilization across the "tripartite interface", a conserved structural hub centered around Domain C. This local perturbation propagates through region 962-977 to the trimer interface, driving time-dependent S-trimer disassembly, as further supported by nsEM. Combining these insights, eight fully conserved residues within the tripartite interface were identified as critical hotspots, representing potential targets for broad-spectrum antibodies capable of inducing trimer disassembly. Together, these findings establish a structure-dynamics framework for rational antibody design, emphasizing the targeting of conserved, conformation-sensitive epitopes to outpace viral immune evasion. Moreover, this work highlights pulsed HDX-MS as a powerful approach for resolving antibody-mediated dynamic regulation of the SARS-CoV-2 spike protein, facilitating the development of next-generation broad-spectrum therapeutics against emerging variants.
3. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD.
In this phase II platform module, osimertinib plus datopotamab deruxtecan achieved confirmed ORR of 43% (4 mg/kg) and 36% (6 mg/kg), with median PFS of 9.5 and 11.7 months and durable responses in the 6 mg/kg cohort. Higher-grade toxicities, including interstitial lung disease/pneumonitis, were more frequent at 6 mg/kg but manageable; the overall benefit–risk favored 6 mg/kg as the starting dose with close monitoring.
Impact: Addresses a pressing post-progression need in EGFR-mutated NSCLC by combining an EGFR-TKI with an anti-TROP2 ADC, demonstrating meaningful activity and informing dose selection and safety monitoring.
Clinical Implications: For EGFR-mutated advanced NSCLC after first-line osimertinib, combining osimertinib with datopotamab deruxtecan (preferred starting dose 6 mg/kg) is a potential option in clinical trials, with vigilant monitoring for ADC-related toxicities, especially interstitial lung disease/pneumonitis.
Key Findings
- Confirmed ORR: 43% at 4 mg/kg and 36% at 6 mg/kg Dato-DXd with osimertinib
- Median PFS: 9.5 months (4 mg/kg) vs 11.7 months (6 mg/kg)
- Median DoR: 6.3 months (4 mg/kg) vs 20.5 months (6 mg/kg, estimated ≥16)
- Grade ≥3 AEs: 49% (4 mg/kg) vs 76% (6 mg/kg); ILD/pneumonitis 3% vs 15%
- Dose reductions more frequent at 6 mg/kg (59% vs 23%)
Methodological Strengths
- Prospective phase II platform with standardized RECIST v1.1 endpoints
- Dose-finding across two Dato-DXd levels enabling benefit–risk assessment
Limitations
- Non-randomized, single-module cohorts limit causal inference
- Small sample size with broad CIs; 80% CIs used for ORR
Future Directions: Randomized studies comparing the combination versus standard post-osimertinib options and biomarker-driven selection (e.g., TROP2 expression, resistance mechanisms) are warranted, alongside strategies to mitigate ADC-related ILD.
BACKGROUND: ORCHARD (NCT03944772) was a phase II platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations following progressive disease (PD) on first-line osimertinib. Datopotamab deruxtecan (Dato-DXd) is an anti-TROP2 antibody-drug conjugate approved as monotherapy in EGFR-mutated advanced non-small-cell lung cancer (NSCLC). We report final data from the osimertinib plus Dato-DXd module. METHODS: Eligible patients had EGFR-mutated advanced NSCLC and PD on first-line osimertinib. Patients received oral osimertinib (80 mg once daily) plus intravenous Dato-DXd (4 or 6 mg/kg every 3 weeks). The primary endpoint was investigator-assessed confirmed objective response rate (ORR) per RECIST v1.1. Secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall survival (OS), and safety. RESULTS: Sixty-nine patients received study treatment. Among patients in the 4 mg/kg (N = 35) and 6 mg/kg (N = 34) cohorts, respectively: confirmed ORR was 43% (80% confidence interval [CI] 32-55) and 36% (80% CI 25-49); median PFS was 9.5 (95% CI 7.2-9.8) and 11.7 (95% CI 8.3-21.7) months; median DoR was 6.3 (95% CI 3.8-8.1) and 20.5 (95% CI 6.2-not calculable [NC]; estimated median of at least 16) months; median OS was 19.8 (95% CI 13.5-23.3) and 26.2 (95% CI 14.8-NC; estimated median greater than or equal to the 4 mg/kg cohort) months. In the 4 mg/kg and 6 mg/kg cohorts, respectively, grade ≥3 adverse events (AEs) were reported in 49% and 76% of patients; AEs leading to Dato-DXd dose reduction in 23% and 59%; and adjudicated interstitial lung disease/pneumonitis in 3% and 15%. CONCLUSIONS: Osimertinib plus Dato-DXd demonstrated clinical benefit in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib. AEs in the 6 mg/kg cohort were of higher frequency and severity but could be managed with prophylaxis, careful monitoring and dose reduction. The safety profile was consistent with the known profiles of the individual drugs. Considering the overall benefit-risk profile, 6 mg/kg is suggested as the preferred Dato-DXd starting dose for combining with osimertinib 80 mg.